Your browser doesn't support javascript.
Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies.
Arrieta, Oscar; Lara-Mejía, Luis; Bautista-GonzÁlez, Elysse; Heredia, David; Turcott, Jenny G; BarrÓn, Feliciano; Ramos-Ramírez, Maritza; Cabrera-Miranda, Luis; Salinas Padilla, Miguel Ángel; Aguerrebere, Mercedes; Cardona, Andrés F; Rolfo, Christian; Arroyo-HernÁndez, Marisol; Soto-Pérez-de-Celis, Enrique; Baéz-Saldaña, Renata.
  • Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Lara-Mejía L; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Bautista-GonzÁlez E; Institute of Epidemiology and Public Health, University College London, London, United Kingdom.
  • Heredia D; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Turcott JG; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • BarrÓn F; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Ramos-Ramírez M; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Cabrera-Miranda L; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Salinas Padilla MÁ; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Aguerrebere M; Instituto Nacional de Psiquiatría, Mexico City, Mexico.
  • Cardona AF; Clinical and Translational Oncology Group, Clínica del Country, Bogota, Colombia.
  • Rolfo C; Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai, New York, New York, USA.
  • Arroyo-HernÁndez M; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Soto-Pérez-de-Celis E; Instituto Nacional de Ciencias Médicas y Nutrición y Salvador Zubirán (INCMNSZ), Mexico City, Mexico.
  • Baéz-Saldaña R; Instituto Nacional de Enfermedades Respiratorias (INER), Mexico City, Mexico.
Oncologist ; 26(12): 1035-1043, 2021 12.
Article in English | MEDLINE | ID: covidwho-1400968
ABSTRACT

BACKGROUND:

Accumulated evidence indicates that patients with lung cancer are a vulnerable population throughout the pandemic. Limited information is available in Latin America regarding the impact of the pandemic on medical care. The goal of this study was to describe the clinical and social effect of COVID-19 on patients with thoracic cancer and to ascertain outcomes in those with a confirmed diagnosis. MATERIALS AND

METHODS:

This cohort study included patients with thoracic neoplasms within a single institution between March 1, 2020, and February 28, 2021. All variables of interest were extracted from electronic medical records. During this period, the Depression Anxiety and Stress Scale 21 (DASS-2) was applied to evaluate and identify more common psychological disorders.

RESULTS:

The mean age for the total cohort (n = 548) was 61.5 ± 12.9 years; non-small cell lung cancer was the most frequent neoplasm (86.9%), advanced stages predominated (80%), and most patients were under active therapy (82.8%). Any change in treatment was reported in 23.9% of patients, of which 78.6% were due to the COVID-19 pandemic. Treatment delays (≥7 days) were the most frequent modifications in 41.9% of cases, followed by treatment suspension at 37.4%. Patients without treatment changes had a more prolonged progression-free survival and overall survival (hazard ratio [HR] 0.21, p < .001 and HR 0.28, p < .001, respectively). The mean DASS-21 score was 10.45 in 144 evaluated patients, with women being more affected than men (11.41 vs. 9.08, p < .001). Anxiety was reported in 30.5% of cases, followed by depression and distress in equal proportions (18%). Depressed and stressed patients had higher odds of experiencing delays in treatment than patients without depression (odds ratio [OR] 4.5, 95% confidence interval [CI] 1.53-13.23, p = .006 and OR 3.18, 95% CI 1.2-10.06, p = .006, respectively).

CONCLUSION:

Treatment adjustments in patients with thoracic malignancies often occurred to avoid COVID-19 contagion with detrimental effects on survival. Psychological disorders could have a role in adherence to the original treatment regimen. IMPLICATIONS FOR PRACTICE The pandemic has placed an enormous strain on health care systems globally. Patients with thoracic cancers represent a vulnerable population, with increased morbidity and mortality rates. In Mexico, treatment modifications were common during the pandemic, and those who experienced delays had worse survival outcomes. Most treatment modifications were related to a patient decision rather than a lockdown of health care facilities in which mental health impairment plays an essential role. Moreover, the high case fatality rate highlights the importance of improving medical care access. Likewise, to develop strategies facing future threats that may compromise health care systems in non-developed countries.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thoracic Neoplasms / Carcinoma, Non-Small-Cell Lung / COVID-19 / Lung Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Mexico Language: English Journal: Oncologist Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: Onco.13962

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Thoracic Neoplasms / Carcinoma, Non-Small-Cell Lung / COVID-19 / Lung Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Mexico Language: English Journal: Oncologist Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: Onco.13962